¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ü¿Ü½Ä CO2 Á¦°Å ±â±â ¼¼°è ½ÃÀå ±Ô¸ð´Â 1¾ï 3,720¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö CAGR 7.2%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. õ½Ä ¹× COPD ¾ÇÈ È¯ÀÚ¿¡¼ È£Èí¼º »êÁõ ¹× È£Èí ºÎÀü ¾Çȸ¦ ¹æÁöÇϰí ħ½ÀÀû ±â°èÀû ÀΰøÈ£Èí±â »ç¿ë ±â°£À» ´ÜÃàÇϰųª ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù.
ü¿Ü½Ä CO2 Á¦°Å ±â±â´Â °íź»êÇ÷Áõ¼º È£ÈíºÎÀüÀ¸·Î °íÅë¹Þ´Â ȯÀÚ¸¦ À§ÇÑ È¿À²ÀûÀÎ Ä¡·á¹ýÀ¸·Î °£ÁֵǸç, ÀÓ»óÀǻӸ¸ ¾Æ´Ï¶ó ÀÇ·áÁøµµ Æó º¸È£ ȯ±â¸¦ °³¼±ÇÒ ¼ö ÀÖ´Â ÀáÀç·ÂÀÌ ÀÖ½À´Ï´Ù. ü¿Ü½Ä CO2 Á¦°Å ±â±â´Â ÆóÆ÷ÀÇ ºÐº° ȯ±â¸¦ 50% °¨¼Ò½ÃŰ±â¿¡ ÃæºÐÇÑ CO2¸¦ Á¦°ÅÇÒ ¼ö ÀÖÀ¸¸ç, ±× °á°ú PaCO2¸¦ Å©°Ô °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ü¿Ü½Ä CO2 Á¦°Å ±â±â¿Í °ü·ÃµÈ ´Ù¾çÇÑ ÀåÁ¡Àº Àüü ½ÃÀåÀÇ ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ü¿Ü ÀÌ»êÈź¼Ò Á¦°Å ÀåÄ¡´Â È¿°úÀûÀÌ°í ¾ÈÀüÇÏ¸ç ½ÇÇà °¡´ÉÇÕ´Ï´Ù. ¸¸¼ºÆó¼â¼ºÆóÁúȯÀÇ ¾ÇÈ, ±Þ¼º È£Èí°ï¶õ ÁõÈıº µî ü¿Ü ÀÌ»êÈź¼Ò Á¦°Å ÀåÄ¡°¡ µµ¿òÀÌ µÉ ¼ö ÀÖ´Â ÀÓ»ó »óȲ¿¡¼ ȯ±â Áö¿ø¿¡ ü¿Ü ÀÌ»êÈź¼Ò Á¦°Å ÀåÄ¡¸¦ »ç¿ëÇÏ´Â °ÍÀÌ Á¦¾ÈµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èÀûÀ¸·Î COPDÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿µ±¹ ÆóÇùȸ¿¡ µû¸£¸é, ¿µ±¹¿¡¼´Â ¾à 120¸¸ ¸íÀÌ COPD Áø´ÜÀ» ¹Þ°í »ýȰÇϰí ÀÖ½À´Ï´Ù.
ÀÌ ½ÃÀå¿¡¼´Â ¿©·¯ Á¦Á¶¾÷üµéÀÌ ±â¼úÀûÀ¸·Î Áøº¸µÈ Çõ½ÅÀûÀΠü¿Ü½Ä CO2 Á¦°Å ±â±â °³¹ß¿¡ ÁÖ·ÂÇÏ¸ç ½ÃÀå ÀÔÁö¸¦ °ÈÇØ ³ª°¡°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2015³â 11¿ù Alung Technologies´Â Hemolung Respiratory Assist System¿¡ ´ëÇØ FDA·ÎºÎÅÍ EAP(Expedited Access pathway)¸¦ ȹµæÇß½À´Ï´Ù. ¶ÇÇÑ 2016³â 2¿ù, ¾Ë·îÅ×Å©³î·ÎÁö´Â ±âÁ¸ ¹× ½Å±Ô ÅõÀÚÀڷκÎÅÍ 1,200¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» Á¶´ÞÇß½À´Ï´Ù. ÀÌ ÀÚ±Ý Á¶´ÞÀº Hemolung È£Èí º¸Á¶ ½Ã½ºÅÛ(RAS)ÀÇ »ó¿ëÈ¿¡ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.
ü¿Ü ÀÌ»êÈź¼Ò Á¦°Å ÀåÄ¡ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ºÎ¹®Àº º´¿ø ¹× ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ¼ö¿ä Áõ°¡·Î À̾îÁú ¼ö ÀÖ´Â ´Ù¾çÇÑ Ã¼¿Ü½Ä CO2 Á¦°Å ±â±â¸¦ »ç¿ëÇÒ ¼ö Àֱ⠶§¹®¿¡ 2022³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- COPD ºÐ¾ß´Â ECCO2R ÀåÄ¡°¡ È£Èí Ƚ¼ö¿Í È£Èí·®À» °¨¼Ò½ÃÄÑ È£Èí±âÀÇ ³ôÀº È£±â ½Ã°£ »ó¼ö¿¡ ÀûÀÀÇÑ ±ä È£±â ½Ã°£À» °¡Á®¿Ã ¼ö Àֱ⠶§¹®¿¡ 2022³â¿¡ »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- Á¤¸Æ ºÎ¹®Àº µ¿¸Æ ij´¼·¹À̼ÇÀ» ÇÇÇÔÀ¸·Î½á ħ½À¼ºÀÌ ³·°í ȯÀÚÀÇ Á¶±â µ¿¿øÀ» ±â´ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- º´¿ø ºÐ¾ß´Â ½ÅÈï °æÁ¦±¹ÀÇ º´¿ø ¼ö Áõ°¡¿Í ÀÇ·á ¼ºñ½º Á¦°ø¾÷üµéÀÇ °æÀï ½ÉÈ·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì´Â ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÀÌ´Â COPD, ARDSÀÇ À¯º´·ü Áõ°¡¿Í ÷´Ü ü¿Ü ÀÌ»êÈź¼Ò Á¦°Å ÀåÄ¡ÀÇ Ã¤Åà Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ü¿Ü½Ä CO2 ¸Ó½Å
- ¼Ò¸ðǰ
- ±âŸ
Á¦5Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå, ¿ëµµº° Áß¿ä Æ÷ÀÎÆ®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS)
- ¸¸¼º Æó¼â¼º ÆóÁúȯ(COPD)
- Æó ÀÌ½Ä Áß°³
- ±âŸ
Á¦6Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â : ¾×¼¼½º ÃßÁ¤¡¤µ¿Ç⠺м®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå, ¾×¼¼½ºº° Áß¿ä Æ÷ÀÎÆ®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- Á¤¸Æ
- µ¿Á¤¸Æ
Á¦7Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå, ÃÖÁ¾ ¿ëµµº° Áß¿ä Æ÷ÀÎÆ®
- ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : µ¿Çâ°ú ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
- º´¿ø
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- Ŭ¸®´Ð
- ±âŸ
Á¦8Àå ü¿Ü½Ä CO2 Á¦°Å ±â±â : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ªº° Àü¸Á
- Áö¿ªº° ü¿Ü½Ä CO2 Á¦°Å ±â±â ½ÃÀå : ÁÖ¿ä ¸¶ÄÏ Ç÷¹À̽º ¿äÁ¡
- ºÏ¹Ì
- ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- µ§¸¶Å©
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- È£ÁÖ
- ű¹
- Çѱ¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦9Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ȸ»ç/°æÀï ºÐ·ù
- Medtronic
- Getinge AB
- Xenios AG
- ALung Technologies, Inc.
- ESTOR S.P.A.
- Medica S.P.A.
- Aferetica srl
LSH 23.10.27
Extracorporeal CO2 Removal Devices Market Growth & Trends:
The global extracorporeal CO2 removal devices market size is estimated to reach USD 137.2 million, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 7.2% from 2023 to 2030. Technological improvements changed extracorporeal techniques for CO2 removal in promising manner to avoid worsening respiratory acidosis and respiratory failure and to possibly shorten or prevent the duration of invasive mechanical ventilation in patients with exacerbation of asthma and COPD.
Extracorporeal CO2 removal devices is considered to be an efficient therapy for patients suffering from hypercapnia respiratory failure and may allow clinicians as well as healthcare professionals to improve lung protective ventilation. Extracorporeal CO2 removal devices can remove adequate CO2 to allow 50% reduction in alveolar minute ventilation resulting into substantial reduction in PaCO2. Hence, various advantages associated with extracorporeal CO2 removal devices is expected to augment the overall market progression.
Extracorporeal CO2 removal devices are effective, safe and feasible. The usage of extracorporeal CO2 removal devices in ventilation support has been suggested in clinical situations where they may be useful, including exacerbation of chronic obstructive pulmonary disease and acute respiratory distress syndrome. Increasing prevalence of COPD across the globe is predicted to accelerate the market growth. According to the British Lung Association, around 1.2 million people are living with diagnosed COPD in the U.K.
Several manufacturers in the market are focusing on developing technological advanced and innovative extracorporeal CO2 removal devices and strengthen its position in the market. For instance, In November 2015, Alung Technologies received Expedited Access pathway (EAP) from the FDA for its Hemolung Respiratory Assist System. In addition, in February 2016, Alung Technologies received USD 12 million financing from existing as well as new investors. This financing helped in commercialization of Hemolung Respiratory Assist System (RAS).
Extracorporeal CO2 Removal Devices Market Report Highlights:
- The extracorporeal CO2 machines segment held the largest revenue share in 2022 owing to availability of a wide range of extracorporeal CO2 removal devices that may lead to increased demand in hospitals and ambulatory surgical centers
- The COPD segment is expected to hold a considerable market share in 2022 as ECCO2R devices may permit a decrease in respiratory rate and respiratory volume, resulting in elongated expiratory time that is better adapted to high expiratory time constant of respiratory system
- The venovenous segment are expected to grow at the fastest rate during the forecast period as it offers less invasiveness by evading arterial cannulation and has the potential for early mobilization of patients
- The hospitals segment is estimated to witness the fastest growth rate over the forecast timeframe owing to rising number of hospitals in developing economies and increasing competition in healthcare service providers
- North America held the largest market share in market and is anticipated to maintain its dominance over the forecast period
- This is attributable to the growing prevalence of COPD, ARDS, and increasing adoption of advanced extracorporeal CO2 removal devices
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Product
- 1.1.2. Application
- 1.1.3. Access
- 1.1.4. End-use
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Application outlook
- 2.2.3. Access outlook
- 2.2.4. End-use outlook
- 2.3. Competitive Insights
Chapter 3. Extracorporeal CO2 Removal Devices Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Extracorporeal CO2 Removal Devices Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic Landscape
Chapter 4. Extracorporeal CO2 Removal Devices: Product Estimates & Trend Analysis
- 4.1. Extracorporeal CO2 Removal Devices Market: Key Takeaways
- 4.2. Extracorporeal CO2 Removal Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Extracorporeal CO2 machines
- 4.3.1. Extracorporeal CO2 machines market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Disposables
- 4.4.1. Disposables market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Others
- 4.5.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Extracorporeal CO2 Removal Devices: Application Estimates & Trend Analysis
- 5.1. Extracorporeal CO2 Removal Devices Market, By Application Key Takeaways
- 5.2. Extracorporeal CO2 Removal Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Acute respiratory distress syndrome (ARDS)
- 5.3.1. Acute respiratory distress syndrome (ARDS) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Chronic obstructive pulmonary disease (COPD)
- 5.4.1. Chronic obstructive pulmonary disease (COPD) market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Bridge to lung transplant
- 5.5.1. Bridge to lung transplant market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Extracorporeal CO2 Removal Devices: Access Estimates & Trend Analysis
- 6.1. Extracorporeal CO2 Removal Devices Market, By Access Key Takeaways
- 6.2. Extracorporeal CO2 Removal Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Venovenous
- 6.3.1. Venovenous market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Arteriovenous
- 6.4.1. Arteriovenous market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Extracorporeal CO2 Removal Devices: End-use Estimates & Trend Analysis
- 7.1. Extracorporeal CO2 Removal Devices Market, By End-use Key Takeaways
- 7.2. Extracorporeal CO2 Removal Devices Market: Movement & Market Share Analysis, 2022 & 2030
- 7.3. Hospitals
- 7.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4. Ambulatory Surgical Centers
- 7.4.1. Ambulatory surgical centers market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5. Clinics
- 7.5.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.6. Others
- 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Extracorporeal CO2 Removal Devices: Regional Estimates & Trend Analysis
- 8.1. Regional Outlook
- 8.2. Moist Wound Dressing Market by Region: Key Marketplace Takeaway
- 8.3. North America
- 8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.3.2. U.S.
- 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.3.3. Canada
- 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.2. Germany
- 8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.3. France
- 8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.4. Italy
- 8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.5. Spain
- 8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.6. Sweden
- 8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.7. Norway
- 8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.2. China
- 8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.3. India
- 8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.4. Australia
- 8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.5. Thailand
- 8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.6. South Korea
- 8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6.2. Mexico
- 8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6.3. Argentina
- 8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7. MEA
- 8.7.1. Saudi Arabia
- 8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.2. South Africa
- 8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.3. UAE
- 8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.2.1. Medtronic
- 9.2.1.1. Company overview
- 9.2.1.2. Financial performance
- 9.2.1.3. Product benchmarking
- 9.2.1.4. Strategic initiatives
- 9.2.2. Getinge AB
- 9.2.2.1. Company overview
- 9.2.2.2. Financial performance
- 9.2.2.3. Product benchmarking
- 9.2.2.4. Strategic initiatives
- 9.2.3. Xenios AG
- 9.2.3.1. Company overview
- 9.2.3.2. Financial performance
- 9.2.3.3. Product benchmarking
- 9.2.3.4. Strategic initiatives
- 9.2.4. ALung Technologies, Inc.
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. ESTOR S.P.A.
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. Medica S.P.A.
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Aferetica srl
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives